

REMARKS

Reconsideration of this application is respectfully request.

Claims 1, 2 and 9-66 are presently pending in this application. Claims 2, 9 – 36 and 54 – 66 are allowed. Claims 1 and 37 – 53 are currently rejected.

Claims 1 is amended herein and now includes the provision: “provided that when V is a steroid or non-steroidal anti-inflammatory subunit, L is a peptide.” Support for this amendment can be found in the specification, page 18. No new matter has been added by this amendment.

The Examiner has rejected claims 1 and 37-53, stating that the specification, on page 18, lines 19 – 20 recites that, in the case when V is a steroid or a non-steroidal inflammatory subunit, L is exclusively peptide linker. Claim 1 has been amended to limit the L moiety to a peptide linker when V is a steroid or non-steroidal anti-inflammatory subunit. Therefore, applicants respectfully request that this rejection for claims 1, 37 – 51, and 53 be withdrawn.

Applicants further request that the rejection of claim 52, containing a particular peptide sequence as a further limitation of allowed claim 2, be withdrawn.

Since, the present amendment places the application in condition for allowance and does not require further consideration and/or searching by the Examiner, the present amendment should be entered.

Dated: June 24, 2005

Respectfully submitted,

By

Lydia Gayle Olson

Registration No.: 48,487

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant